Insider Selling: Longeveron Inc. (NASDAQ:LGVN) CFO Sells 36,955 Shares of Stock

Longeveron Inc. (NASDAQ:LGVNGet Rating) CFO James Clavijo sold 36,955 shares of the business’s stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $8.26, for a total transaction of $305,248.30. Following the completion of the sale, the chief financial officer now directly owns 79,619 shares of the company’s stock, valued at approximately $657,652.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ:LGVN traded down $0.45 during trading on Tuesday, reaching $7.41. 202,853 shares of the company traded hands, compared to its average volume of 3,362,360. The firm has a market capitalization of $155.15 million, a PE ratio of -8.65 and a beta of -1.93. Longeveron Inc. has a 52 week low of $2.84 and a 52 week high of $45.00. The company’s 50 day moving average is $9.37 and its two-hundred day moving average is $10.75.

Longeveron (NASDAQ:LGVNGet Rating) last posted its quarterly earnings results on Friday, May 13th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. Longeveron had a negative return on equity of 58.76% and a negative net margin of 1,341.85%. During the same period in the prior year, the firm earned ($0.18) earnings per share. As a group, sell-side analysts forecast that Longeveron Inc. will post -0.7 EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. Royal Bank of Canada bought a new stake in shares of Longeveron during the 2nd quarter worth approximately $28,000. Geode Capital Management LLC raised its position in Longeveron by 45.6% during the third quarter. Geode Capital Management LLC now owns 21,530 shares of the company’s stock valued at $76,000 after purchasing an additional 6,742 shares in the last quarter. UBS Group AG lifted its stake in Longeveron by 272.9% during the third quarter. UBS Group AG now owns 9,633 shares of the company’s stock worth $34,000 after purchasing an additional 7,050 shares during the last quarter. TownSquare Capital LLC acquired a new stake in shares of Longeveron in the 3rd quarter valued at $51,000. Finally, Alps Advisors Inc. bought a new position in shares of Longeveron in the 4th quarter valued at $267,000. Institutional investors own 2.20% of the company’s stock.

Separately, Maxim Group started coverage on shares of Longeveron in a research report on Thursday, March 24th. They issued a “buy” rating and a $14.00 price target for the company.

About Longeveron (Get Rating)

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors.

Further Reading

Insider Buying and Selling by Quarter for Longeveron (NASDAQ:LGVN)

Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with's FREE daily email newsletter.